[1]黄健, 张旭. 中国泌尿外科和男科疾病诊断治疗指南: 2022版[M]. 北京: 科学出版社, 2022.
[2]汪涵, 樊俊宁, 余灿清, 等. 中国成年人体质指数和腰围与肾结石住院风险的关联研究[J]. 中华流行病学杂志, 2022, 43(2): 154-161.
[3]娄路馨, 于爱红, 李凯, 等. 中国社区40岁以上人群无症状肾结石患病率的CT调查[J]. 中国全科医学, 2020, 23(22): 2793-2796.
[4]郭瑞祥, 李昱卓, 何綦琪. 代谢综合征参与不同成分肾结石发病机制研究进展[J]. 临床泌尿外科杂志, 2019, 34(1): 69-73.
[5]Ergani B, Türk H, Karabak M, et al. Specific effects of some metabolic syndrome components on kidney stone formation: a multicentric multidisciplinary study[J]. J Urol Surg, 2022, 9(4): 241-245.
[6]Geraghty RM, Cook P, Roderick P, et al. Risk of metabolic syndrome in kidney stone formers: A comparative cohort study with a median followup of 19 years[J]. J Clin Med, 2021, 10(5): 978.
[7]曹程, 丁琪, 范波, 等. 血脂异常与肾结石发生风险的关系[J]. 中华实验外科杂志, 2018, 35(3): 558-560.
[8]Welsh A, Hammad M, Pia IL, et al. Obesity and cardiovascular health[J]. Eur J Prev Cardiol, 2024, Jan 19: zwae025. doi: 10.1093/eurjpc/zwae025.Epub ahead of print.
[9]Mrz W, Kleber M, Grammer TB, et al. Lipid metabolism and kidney diseases: Where do we stand in 2013?[J]. Nieren Hochdruck, 2013, 42(9): 417-424.
[10]Brennan E, Kantharidis P, Cooper ME, et al. Proresolving lipid mediators: regulators of inflammation, metabolism and kidney function[J]. Nat Rev Nephrol, 2021, 17(11): 725-739.
[11]Kostogrys RB, FranczykZ·arów M, Mas'lak E, et al. Effect of low carbohydrate high protein (LCHP) diet on lipid metabolism, liver and kidney function in rats[J]. Environ Toxicol Pharmacol, 2015, 39(2): 713-719.
[12]Xu M, Jiang F, Li B, et al. 1α,25(OH)2D3 alleviates high glucoseinduced lipid accumulation in rat renal tubular epithelial cells by inhibiting SREBPs[J]. J Cell Biochem, 2019, 120(9): 15211-15221.
[13]Letavernier E, Bazin D, Daudon M. Randall′s plaque and kidney stones: Recent advances and future challenges[J]. CR Chim, 2015, 19(11/12): 1456-1460.
[14]何綦琪, 吴晃, 李昱卓, 等. 线粒体功能障碍在肾结石成石中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 306-310.
[15]Li G, Liang H, Hao Y, et al. Association between body fat distribution and kidney stones: Evidence from a US population[J]. Front Endocrinol (Lausanne), 2022, 13: 1032323.
[16]Hung J, Li C, Geng J, et al. Dyslipidemia increases the risk of incident kidney stone disease in a large Taiwanese population followup study[J]. Nutrients, 2022, 14(7): 1339.
[17]Flisiński M, Brymora A, SkoczylasMakowska N, et al. Fructoserich diet is a risk factor for metabolic syndrome, proximal tubule injury and urolithiasis in rats[J]. Int J Mol Sci, 2021, 23(1): 203.
[18]He Q, Tang Y, Li Y, et al. A pilot dynamic analysis of formative factors of nephrolithiasis related to metabolic syndrome: evidence in a rat model[J]. Ren Fail, 2022, 44(1): 1134-1143.
[19]Wang Y, Nakajima T, Gonzalez FJ, et al. PPARs as metabolic regulators in the liver: lessons from liverspecific PPARnull mice[J]. Int J Mol Sci, 2020, 21(6): 2061.
[20]Chao Y, Li N, Xiong S, et al. Lipidomics based on liquid chromatographyhigh resolution mass spectrometry reveals the protective role of peroxisome proliferatoractivated receptor alpha on kidney stone formation in mice treated with glyoxylate[J]. J Sep Sci, 2023, 46(24): e2300452.
[21]Taguchi K, Okada A, Hamamoto S, et al. Differential roles of peroxisome proliferatoractivated receptorα and receptorγ on renal crystal formation in hyperoxaluric rodents[J]. PPAR Res, 2016, 2016: 9605890.
[22]Su M, Sang S, Liang T, et al. PPARG: a novel target for yellow tea in kidney stone prevention[J]. Int J Mol Sci, 2023, 24(15): 11955.
[23]Liu YD, Yu SL, Wang R, et al. Rosiglitazone suppresses calcium oxalate crystal binding and oxalateinduced oxidative stress in renal epithelial cells by promoting PPARγ activation and subsequent regulation of TGFβ1 and HGF expression[J]. Oxid Med Cell Longev, 2019, 2019: 4826525.
[24]Liu Y, Chen S, Liu J, et al. Telmisartan inhibits oxalate and calcium oxalate crystalinduced epithelialmesenchymal transformation via PPARγAKT/STAT3/p38 MAPKSnail pathway[J]. Life Sci, 2020, 241: 117108.
[25]Li S, Lan Y, Wu W, et al. Peroxisome proliferatoractivated receptor γ modulates renal crystal retention associated with high oxalate concentration by regulating tubular epithelial cellular transdifferentiation[J]. J Cell Physiol, 2019, 234(3): 2837-2850.
[26]Lee CH, Lui DTW, Lam KSL. Adipocyte fatty acidbinding protein, cardiovascular diseases and mortality[J]. Front Immunol, 2021, 12: 589206.
[27]Wang G, Bonkovsky HL, de Lemos A, et al. Recent insights into the biological functions of liver fatty acid binding protein 1[J]. J Lipid Res, 2015, 56(12): 2238-2247.
[28]Guzmn C, Benet M, PisoneroVaquero S, et al. The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα, and repressed by C/EBPα: Implications in FABP1 downregulation in nonalcoholic fatty liver disease[J]. Biochim Biophys Acta, 2013, 1831(4): 803-818.
[29]Kashani K, Cheungpasitporn W, Ronco C. Biomarkers of acute kidney injury: the pathway from discovery to clinical adoption[J]. Clin Chem Lab Med, 2017, 55(8): 1074-1089.
[30]Taguchi K, Chen L, Usawachintachit M, et al. Fatty acidbinding protein 4 downregulation drives calcification in the development of kidney stone disease[J]. Kidney Int, 2020, 97(5): 1042-1056.
[31]Bargagli M, Ferraro PM, Vittori M, et al. Calcium and vitamin D supplementation and their association with kidney stone disease: a narrative review[J]. Nutrients, 2021, 13(12): 4363.
[32]Messa P, Castellano G, Vettoretti S, et al. Vitamin D and calcium supplementation and urolithiasis: a controversial and multifaceted relationship[J]. Nutrients, 2023, 15(7): 1724.
[33]Kovacevic L, Lu H, Caruso JA, et al. Marked increase in urinary excretion of apolipoproteins in children with nephrolithiasis associated with hypercalciuria[J]. Pediatr Nephrol, 2017, 32(6): 1029-1033.
[34]Zhu W, Liu M, Wang GC, et al. Fibrinogen alpha chain precursor and apolipoprotein AⅠ in urine as biomarkers for noninvasive diagnosis of calcium oxalate nephrolithiasis: a proteomics study[J]. Biomed Res Int, 2014, 2014: 415651.
[35]Wong TY, Wu CY, Martel J, et al. Detection and characterization of mineraloorganic nanoparticles in human kidneys[J]. Sci Rep, 2015, 5: 15272.
[36]Yang Y, Hong S, Li C, et al. Proteomic analysis reveals some common proteins in the kidney stone matrix[J]. PeerJ, 2021, 9: e11872.
[37]Zhou R, Ma Y, Liu Z, et al. The neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for monitoring renal function in patients with solitary kidney stones: a singlecenter, retrospective analysis of 23 cases[J]. Arch Esp Urol, 2022, 75(10): 849-853.
[38]Bhardwaj R, Bhardwaj A, Dhawan D, et al. 4PBA rescues hyperoxaluria induced nephrolithiasis by modulating urinary glycoproteins: Cross talk between endoplasmic reticulum, calcium homeostasis and mitochondria[J]. Life Sci, 2022, 305: 120786.
[39]Chaiyarit S, Thongboonkerd V. Mitochondrial dysfunction and kidney stone disease[J]. Front Physiol, 2020, 11: 566506.
[40]Sharma M, Sud A, Kaur T, et al. Nacetylcysteine with apocynin prevents hyperoxaluriainduced mitochondrial protein perturbations in nephrolithiasis[J]. Free Radic Res, 2016, 50(9): 1032-1044.
[41]周凯, 赵嘉闻, 黎承杨, 等. 草酸钙晶体诱导肾小管上皮细胞铁死亡的体外研究[J]. 中华实验外科杂志, 2021, 38(8): 1601-1604.
[42]万文龙, 吴维松, 依日夏提江·阿米尔, 等. 铁死亡在肾结石形成中的研究进展[J]. 中华实验外科杂志, 2022, 39(4): 814-816.
[43]Song Q, Liao W, Chen X, et al. Oxalate activates autophagy to induce ferroptosis of renal tubular epithelial cells and participates in the formation of kidney stones[J]. Oxid Med Cell Longev, 2021, 2021: 6630343.
[44]He Z, Liao W, Song Q, et al. Role of ferroptosis induced by a high concentration of calcium oxalate in the formation and development of urolithiasis[J]. Int J Mol Med, 2021, 47(1): 289-301.
[45]Pope LE, Dixon SJ. Regulation of ferroptosis by lipid metabolism[J]. Trends Cell Biol, 2023, 33(12): 1077-1087.
[46]Singh R, Cuervo AM. Lipophagy: connecting autophagy and lipid metabolism[J]. Int J Cell Biol, 2012, 2012: 282041.
[47]Li H, Zhou Y, Xu W, et al. The role of autophagy in calcium oxalate kidney stone: A systematic review of the literature[J]. Front Physiol, 2022, 13: 1008264.
[48]Sun Y, Kang J, Tao Z, et al. Effect of endoplasmic reticulum stressmediated excessive autophagy on apoptosis and formation of kidney stones[J]. Life Sci, 2020, 244: 117232.
[49]李洪叶, 刘明明, 李媛, 等. 微小RNA在糖尿病肾脏病中的研究进展[J]. 江苏大学学报(医学版), 2022, 32(4): 359-362, 368.
[50]丁静, 张莉玲, 陈珏通, 等. 代谢综合征与早期肾功能损害的关系[J]. 江苏大学学报(医学版), 2008, 18(1): 67-69,72.
[51]Radosz A, Obuchowicz A. Lipid metabolism and renal function markers in obese adolescents[J]. Pediatr Endocrinol Diabetes Metab, 2023, 29(2): 91-96.
|